Xeris Pharmaceuticals last year snared approval for its first drug, a shelf-stable glucagon injector for hypoglycemia. Now it's deploying its formulation tech to hit another target—epilepsy—and the ...
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback